Hypofractionated Expedited Radiotherapy for Men With localisEd proState Cancer

The purpose of this research is to investigate whether stereotactic body radiotherapy (SBRT), precise X-ray treatment, is best given in five treatments (also called fractions) over 10 days or in two treatments over 8 days. SBRT is an accurate way to deliver a high dose of radiotherapy to the prostate in a smaller number of doses. We have considerable experience with 5-dose SBRT and now wish to examine the feasibility and safety of delivering treatment over two, larger, doses. Previous work has shown it is theoretically possible to deliver two fraction SBRT on the MR-linac and previous studies

Trial Details

NCT ID

NCT04595019

Phase

NA

Sponsor

Institute of Cancer Research, United Kingdom

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

• SBRT

Locations (sample)

• Sutton, Surrey, United Kingdom|51.35,-0.2

Key Eligibility Criteria

• Men aged ≥18 years
• Histological confirmation of prostate adenocarcinoma requiring radical radiotherapy
• Gleason score 3+4 or 4+3 (Grade groups 2 or 3)
• MRI stage T3a or less

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →